128 related articles for article (PubMed ID: 36732986)
1. [Cases of Advanced Colorectal Cancer with Nephrotic Syndrome after FOLFIRI plus Ramucirumab Administration].
Nakura M; Nojima K; Yamazaki H; Takenaka S; Watanabe T; Takeshita M; Sasaki S; Fujimura T
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1745-1747. PubMed ID: 36732986
[TBL] [Abstract][Full Text] [Related]
2. [A Case of Nephrotic Syndrome Induced by FOLFIRI plus Ramucirumab for Metastatic Descending Colon Cancer].
Shingai T; Fukuzaki T; Okimura S; Ito Y; Taniguchi Y; Fukata T; Nishida H; Takayama O; Yoshioka S; Hojo S; Ohigashi H
Gan To Kagaku Ryoho; 2019 Dec; 46(13):2155-2157. PubMed ID: 32156863
[TBL] [Abstract][Full Text] [Related]
3. Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study.
Dote S; Shiwaku E; Kohno E; Fujii R; Mashimo K; Morimoto N; Yoshino M; Odaira N; Ikesue H; Hirabatake M; Takahashi K; Takahashi M; Takagi M; Nishiuma S; Ito K; Shimato A; Itakura S; Takahashi Y; Negoro Y; Shigemori M; Watanabe H; Hayasaka D; Nakao M; Tasaka M; Goto E; Kataoka N; Yokomizo A; Kobayashi A; Nakata Y; Miyake M; Hayashi Y; Yamamoto Y; Hirata T; Azuma K; Makihara K; Fukui R; Tokutome A; Yagisawa K; Honda S; Meguro Y; Suzuki S; Yamaguchi D; Miyata H; Kobayashi Y;
Int J Clin Oncol; 2023 Aug; 28(8):1054-1062. PubMed ID: 37261583
[TBL] [Abstract][Full Text] [Related]
4. [Experience of Ramucirumab plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer in Our Hospital].
Hagino S; Miyata T; Sakamoto K
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1559-1561. PubMed ID: 29394701
[TBL] [Abstract][Full Text] [Related]
5. [FOLFIRI plus RAM Therapy in Later Line of Unresectable Colorectal Cancer].
Naito A; Imasato M; Iwamoto K; Takeda M; Hyuga S; Ohashi T; Nakahara Y; Furukawa K; Moon J; Asaoka T; Mizushima T
Gan To Kagaku Ryoho; 2023 Jan; 50(1):113-115. PubMed ID: 36760004
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
Yamazaki K; Nagase M; Tamagawa H; Ueda S; Tamura T; Murata K; Eguchi Nakajima T; Baba E; Tsuda M; Moriwaki T; Esaki T; Tsuji Y; Muro K; Taira K; Denda T; Funai S; Shinozaki K; Yamashita H; Sugimoto N; Okuno T; Nishina T; Umeki M; Kurimoto T; Takayama T; Tsuji A; Yoshida M; Hosokawa A; Shibata Y; Suyama K; Okabe M; Suzuki K; Seki N; Kawakami K; Sato M; Fujikawa K; Hirashima T; Shimura T; Taku K; Otsuji T; Tamura F; Shinozaki E; Nakashima K; Hara H; Tsushima T; Ando M; Morita S; Boku N; Hyodo I
Ann Oncol; 2016 Aug; 27(8):1539-46. PubMed ID: 27177863
[TBL] [Abstract][Full Text] [Related]
7. Comparative Cost-effectiveness of Aflibercept and Ramucirumab in Combination with Irinotecan and Fluorouracil-based Therapy for the Second-line Treatment of Metastatic Colorectal Cancer in Japan.
Kashiwa M; Matsushita R
Clin Ther; 2020 Jul; 42(7):1361-1375. PubMed ID: 32616433
[TBL] [Abstract][Full Text] [Related]
8. Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor.
Yamazaki K; Yuki S; Oki E; Sano F; Makishima M; Aoki K; Hamano T; Yamanaka T
Clin Colorectal Cancer; 2021 Sep; 20(3):e173-e184. PubMed ID: 33875364
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies.
Ohtani H; Arimoto Y; Nishio K; Kanamiya Y; Oba H; Adachi K; Shintani M; Nakamura R; Yui S
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1769-74. PubMed ID: 18931586
[TBL] [Abstract][Full Text] [Related]
10. [A case of long-term survival following chemotherapy after laparoscopic resection of sigmoid colon cancer with multiple liver metastases].
Ohashi I; Arai I; Tamura C; Hayashi N; Inoue S; Wakasa T
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1758-60. PubMed ID: 25731320
[TBL] [Abstract][Full Text] [Related]
11. Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer.
Suzuki T; Shinozaki E; Osumi H; Nakayama I; Ota Y; Ichimura T; Ogura M; Wakatsuki T; Ooki A; Takahari D; Suenaga M; Chin K; Yamaguchi K
Cancer Chemother Pharmacol; 2019 Aug; 84(2):307-313. PubMed ID: 31065729
[TBL] [Abstract][Full Text] [Related]
12. [Nephrotic Syndrome Induced by Ramucirumab for Metastatic Rectal Cancer].
Sakabe R; Shirakawa K; Yoshimura K; Otsuka H; Kuwada A; Tahara K; Hotei H; Maeda Y
Gan To Kagaku Ryoho; 2018 Aug; 45(8):1205-1207. PubMed ID: 30158421
[TBL] [Abstract][Full Text] [Related]
13. [Comparative Safety Assessment of Ramucirumab plus FOLFIRI and Bevacizumab plus FOLFIRI in Second- and Later-Line Treatment in Japanese Patients with Metastatic Colorectal Carcinoma].
Iwai M; Kimura M; Usami E; Yoshimura T
Gan To Kagaku Ryoho; 2022 Jun; 49(6):687-691. PubMed ID: 35799397
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS
Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064
[TBL] [Abstract][Full Text] [Related]
15. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
[TBL] [Abstract][Full Text] [Related]
16. Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database.
Shinozaki E; Makiyama A; Kagawa Y; Satake H; Tanizawa Y; Cai Z; Piao Y
PLoS One; 2021; 16(2):e0246160. PubMed ID: 33556095
[TBL] [Abstract][Full Text] [Related]
17. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
18. [A case of sigmoid colon cancer with peritoneal dissemination responding to third-line therapy employing bevacizumab combination therapy after failure of FOLFOX and FOLFIRI].
Tamura T; Ishikawa N; Koui S; Nakashima H; Minagawa N; Hachiya Y; Hirata K; Sako T; Fukuyama T; Hirano Y
Gan To Kagaku Ryoho; 2010 Sep; 37(9):1813-6. PubMed ID: 20841954
[TBL] [Abstract][Full Text] [Related]
19. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J; Yoshino T; Cohn AL; Obermannova R; Bodoky G; Garcia-Carbonero R; Ciuleanu TE; Portnoy DC; Van Cutsem E; Grothey A; Prausová J; Garcia-Alfonso P; Yamazaki K; Clingan PR; Lonardi S; Kim TW; Simms L; Chang SC; Nasroulah F;
Lancet Oncol; 2015 May; 16(5):499-508. PubMed ID: 25877855
[TBL] [Abstract][Full Text] [Related]
20. [A case of unresectable and multiple advanced primary cancers of the stomach and rectosigmoid colon with hepatic metastases successfully treated with FOLFIRI for local control of a gastric lesion].
Aoyagi H; Kaneko J; Ono H; Isogai J; Yoshida M; Someno Y; Katsuta E; Saguchi M; Takahata T; Hasegawa K; Hamada S; Higuchi T; Sugihara K; Maejima S
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2433-5. PubMed ID: 21224597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
